US/UK/Canada

Share

Pick a time period -
Tags ( Active)

‘DR. PHIL’ SHOW TO FEATURE GENOMIND’S GENECEPT ASSAY™ IN UPCOMING PROGRAM AIMED AT HELPING A PATIENT GET BETTER, FASTER

Genomind (www.genomind.com), a personalized medicine company bringing innovation to mental health care through genetic testing, will soon be featured in a nationally broadcast episode of “Dr. Phil.” Dr. Phil McGraw, a psychologist and New York Times best-selling author, and his producers selected Genomind’s Genecept Assay ™ to be highlighted as part of a program focused on helping a family in crisis. The Genecept Assay is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It is an easily administered cheek swab test that

DR. JAY LOMBARD OF GENOMIND SELECTED TO SPEAK AT PARTNERING FOR CURES (P4C) ON “MENTAL HEALTH: RESEARCH AND DEVELOPMENT AT A CROSSROADS”

Genomind Co-Founder and Neurologist Challenges Conventional Thinking about Brain DisordersDr. Jay Lombard of Genomind, a personalized medicine company, will speak to the challenges of diagnosing and treating brain disorders at the Partnering for Cures Conference in New York City at the Grand Hyatt Hotel November 3-5, 2013. FasterCures is a center of the Milken Institute. Now in its fifth year, this conference continues to draw medical innovators from across sectors of the research and development ecosystem. This year's Partnering for Cures program will feature 16 panels addressing

GENOMIND MICROSITE WINS “BEST IN CLASS” AWARD

Genecept™ Assay microsite awarded highest honor in 2013 Interactive Media Awards.Genomind, a personalized medicine company, was awarded “Best in Class” for their Genecept™ Assay microsite, geneceptassay.com, during the 2013 annual Interactive Media Awards. The “Best in Class” award is the highest honor awarded in the competition and represents the very best in planning, execution, and overall professionalism. During a comprehensive judging process, sites are reviewed for their design, content, functionality, usability, and browser compatibility. The Genecept Assay microsite won high

GENOMIND TO PARTICIPATE IN NAPHS ANNUAL MEETING

Genomind continues relationship with the National Association of Psychiatric Health SystemsGenomind, a personalized medicine company, is pleased to announce their participation at the National Association of Psychiatric Health Systems Annual Meeting, to be held March 11-13, 2013, in Washington, DC. This will be Genomind’s third year attending and exhibiting at this meeting. NAPHS is a national organization that advocates for behavioral health and represents provider systems which serve patients with mental and substance abuse disorders. The NAPHS Annual Meeting is a gathering of

GENOMIND TO SPEND WEEK EDUCATING INDUSTRY LEADERS

Activities to include interactive webinar and exhibition at NPA's Psychopharmacology Update conferenceGenomind, a personalized medicine company, is pleased to embark on a solid week of education and promotion of the Genecept™ Assay. This week, Genomind will be hosting both an informational webinar and exhibiting at the Nevada Psychiatric Association 18th Annual Psychopharmacology Update conference. Today, Genomind will host a complimentary educational webinar, “From Treating Illness to Treating Individuals: How Biomarkers Are Advancing Psychiatry,” featuring Dr. Jay Lombard, Chief

GENOMIND TO EXHIBIT AT TWO UPCOMING MENTAL HEALTH CONFERENCES

Staff to share latest advancements with attendees of APNA and Psych Congress.Genomind, a personalized medicine company for neuropsychiatry, is excited to announce that company representatives will be attending and exhibiting at the American Psychiatric Nurses Association Annual Conference and the U.S. Psychiatric and Mental Health Congress, two respected conventions of mental health professionals that will occur this week. Genomind will be on hand to share the most recent research and advancements in the field of personalized medicine, including their groundbreaking GeneceptTM Assay, a

GENOMIND ANNOUNCES NEW PORTAL AT NEI GLOBAL PSYCHOPHARMACOLOGY CONGRESS

Presentation by CSO Dr. Lombard to showcase the Genecept™Assay and portal highlights.Genomind, a personalized medicine company for neuropsychiatry, is excited to announce its new clinician online portal at the Neuroscience Education Institute (NEI) Global Psychopharmacology Congress in San Diego. Genomind will host a Product Theater at the Congress on Saturday, October 20, 2012 at 7 am, where co-founder and Chief Scientific Officer Dr. Jay Lombard will discuss the Company’s Genecept Assay, introduce attendees to the new system, and showcase the convenient features for clinicians. The

MEDIA ALERT

GENOMIND PRESENTS WEBINAR SHOWCASING BENEFITS OF THE GENECEPT™ ASSAYCHALFONT, PA – October 9, 2012—Genomind is pleased to announce that on October 9 and 10, 2012, they will host a complimentary educational webinar featuring Dr. Jay Lombard, Chief Scientific Officer and Medical Director. All those interested in learning more about biomarkers in psychiatry are invited to join. Dr. Lombard will present a session about the importance of biomarkers in psychiatry, and the clinical application and benefits provided by Genomind’s Genecept Assay. The Assay is a simple to use, saliva-based test

Rudolph E. Tanzi, Ph.D. Joins Genomind’s Scientific Advisory Board

Dr. Tanzi is a global expert on gene research for Alzheimer’sGenomind, LLC, a neuropsychiatric personalized medicine company, recently announced the addition of a new member to its leading Scientific Advisory Board.Rudolph E. Tanzi, Ph.D., is the director of the Genetics and Aging Research Unit at the MassGeneral Institute for Neurodegenerative Disease in Boston. He is also a professor of neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University.                    Dr. Tanzi is an internationally respected

There are no items matching the current filter
There are no more items matching the current filter
Back to top